Apr 09,2024

Tandem Diabetes Care to Announce First Quarter 2024 Financial Results on May 2, 2024

Tandem Diabetes Care plans to release its first quarter 2024 results after the financial markets close on Thursday, May 2, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2024 financial and operating results.

View Analyst & Ambassador Comments
Go to original news
Apr 10,2024

Newfoundland and Labrador expands access to continuous glucose monitoring program

Newfoundland & Labrador (Canada)'s Government expands its continuous glucose monitoring program in Budget 2024, now including patients up to age 25 with type 1 diabetes (T1D) enrolled in the NL Insulin Pump Program and pregnant individuals with gestational diabetes. Previously limited to those under 18, a one-year pilot project paved the way for this expansion. With an investment of nearly $1.8 million, the program becomes permanent, benefiting from JDRF Canada's support.

PRODUCT

#reimbursement

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 26,2024

Kakao Healthcare and Brave Company team up to spread blood sugar management content

Kakao Healthcare has partnered with Brave Company, a healthcare startup, to develop and distribute exercise content aimed at proper blood sugar management. The collaboration involves Kakao Healthcare's medical experts and Brave Company's exercise experts jointly creating customized content, which will be available on various platforms including Kakao Healthcare's PASTA. Brave Company will also share the content across its healthcare platforms and collaborate with health-related creators to enhance accessibility. Both companies aim to provide easy-to-access and enjoyable exercise content for users, promoting public health and offering a scientific healthcare experience.

COLLABORATION PARTNERSHIP

#r&d

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 04,2024

Teladoc Health CEO Jason Gorevic departs after stock falls 22% in February

Jason Gorevic, the CEO and board member of Teladoc Health, is resigning after 15 years, with Mala Murthy, the CFO, stepping in as acting CEO. The departure follows a significant stock drop of 22% in February, missed earnings estimates, and lower-than-expected revenue projections for 2024. The company plans to find a permanent replacement and has retained an executive search firm for this purpose. Despite financial challenges, Teladoc saw revenue growth in 2023, particularly from its BetterHelp and integrated care segments. The company is maintaining its guidance for the first quarter and full year of 2024.

View Analyst & Ambassador Comments
Go to original news
Apr 01,2024

GLUCOTRACK ANNOUNCES INCREASED SENSOR LONGEVITY FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR

Glucotrack, a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, and The Technology Partnership (“TTP”), announced the completion of computational modeling for Glucotrack’s implantable Continuous Blood Glucose Monitor, suggesting sensor longevity beyond three years, a year longer than the Company previously announced. Glucotrack has engaged TTP for the development of computational modeling, which addresses enzyme longevity for use in long-term implantable electrochemical sensors. This in silico modeling specifically evaluated the expected longevity of the Glucotrack CBGM sensor implementation. The CBGM sensor leverages well-established cardiovascular technology to directly measure blood glucose intravenously, providing more rapid glucose monitoring results without the 15-20-minute lag seen with interstitial glucose sensors.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 01,2024

TWO NATIONAL EMPLOYERS SELECT DARIO'S INTEGRATED CHRONIC CONDITION SOLUTION TO IMPROVE EMPLOYEE HEALTH

DarioHealth announced two new contracts to provide integrated chronic condition management solutions for two national employers beginning in the second quarter of 2024. The first employer, a global private investment group, selected Dario's cardiometabolic suite to help improve outcomes for employees with cardiometabolic health conditions, including diabetes, pre-diabetes, hypertension and weight management needs, and support for individuals taking a GLP-1. The second employer, a national professional services company, selected Dario's full suite of solutions to deliver personalized support for employees living with cardiometabolic health conditions and commonly co-occurring MSK and behavioral health needs.

PRODUCT

#coaching

View Analyst & Ambassador Comments
Go to original news
Mar 26,2024

Efficacy of a Digital Diabetes Logbook for People With Type 1, Type 2, and Gestational Diabetes: Results From a Multicenter, Open-Label, Parallel-Group, Randomized Controlled Trial

This randomized controlled trial with a 12-week follow-up was conducted in 41 study sites across Germany, and assessed the effectiveness of a digital diabetes diary in reducing diabetes distress. Participants were randomly assigned to use the mySugr PRO app or no app (control group). A total of 397 participants completed the trial (drop-out rate: 6.4%). Results showed a significant reduction in diabetes distress in the intervention group compared to the control group. The study suggests that the digital diary could improve mental health in individuals with type 1, type 2, and gestational diabetes.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 31,2024

Comparative Effectiveness of Hybrid Closed-Loop Automated Insulin Delivery Systems Among Patients with Type 1 Diabetes

This retrospective clinical study compared outcomes of patients with type 1 diabetes using different hybrid closed-loop (HCL) systems in a real-world setting. The study included patients from an academic endocrinology practice who were new to any HCL system between January 1, 2018, and November 18, 2022. The outcomes assessed were the percentage of time spent in the target glucose range (TIR), percentage of time spent below the target range (TBR), and changes in HbA1c levels. Results showed that there were significant reductions in HbA1c levels with Tandem Control IQ (CIQ) and Omnipod 5 (OP5), but not with Medtronic 670G/770G (MT). TIR was similar across all three systems, but TBR was highest with MT. In conclusion, while all HCL systems showed improvements in certain outcomes, there were differences in TBR, with MT having the highest rates. The differences in the percentage of time in automated delivery likely explain variations in HbA1c changes but not in TBR between HCL systems.

CLINICAL STUDY

#closed loop

View Analyst & Ambassador Comments
Go to original news
Mar 27,2024

ABBOTT HOSTS CONFERENCE CALL FOR FIRST-QUARTER EARNINGS

Abbott will announce its first-quarter 2024 financial results on Wednesday, April 17, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.

View Analyst & Ambassador Comments
Go to original news
Mar 21,2024

New Research Shows Long-Term A1C Reduction and Sustained Weight Maintenance in Omada Health’s Type 2 Diabetes Program

Omada Health recently published its 28th peer-reviewed study demonstrating the long-term outcomes of utilizing a behavior change program for members with T2D. The study, published in The Science of Diabetes Self-Management and Care,  come on the heels of the company’s Insights Lab expansion, which established the ANSWERS initiative to focus on insights derived from combining GLP-1s with a proven behavior change approach. Researchers analyzed data from more than 1,000 commercially insured members with T2D who were enrolled between January 1, 2019, and January 31, 2022, in Omada’s virtual care solution. Within this group, changes in A1C levels and weight were examined over 12 months. Key results show that members with elevated A1C (over or equal to 8%) at baseline experienced an average 1.8-point decline in A1C over 12 months. Also, members collectively experienced an average reduction of 7.3 pounds over 12 months.

CLINICAL STUDY

#virtual care

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES